Latest developments in anticoagulant drug discovery

被引：6
作者：
Broussalis, Erasmia [1 ,2 ,3 ]
Anna, Wallner [2 ]
Trinka, Eugen [3 ]
Mutzenbach, Sebastian [3 ]
Killer, Monika [2 ,3 ]
机构：
[1] Paracelsus Med Univ Salzburg, Christian Doppler Klin, Dept Neuroradiol, A-5020 Salzburg, Austria
[2] Paracelsus Med Univ Salzburg, Christian Doppler Klin, Res Inst Neurointervent, A-5020 Salzburg, Austria
[3] Paracelsus Med Univ Salzburg, Christian Doppler Klin, Dept Neurol, A-5020 Salzburg, Austria
来源：
DRUG DISCOVERY TODAY | 2014年 / 19卷 / 07期
关键词：
FACTOR-XA INHIBITOR; ORAL DIRECT THROMBIN; NONVALVULAR ATRIAL-FIBRILLATION; TOTAL KNEE REPLACEMENT; ACUTE CORONARY SYNDROMES; VENOUS THROMBOEMBOLISM; DOUBLE-BLIND; DABIGATRAN ETEXILATE; STROKE PREVENTION; PHASE-II;
D O I：
10.1016/j.drudis.2014.02.011
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Thromboembolic diseases have increased in number over the past years. Oral anticoagulants impair the formation and progression of thrombotic processes and are therefore of great importance in the treatment of these diseases. Until recently, vitamin K antagonists were used to block the coagulation system. But these agents display a lot of interactions besides their narrow therapeutic range and have potential risk of hemorrhage complications. Therefore, other factors of the coagulation cascade are currently being explored as therapeutic targets for the development of novel anticoagulants. This review will provide an overview of new drugs promising more effectiveness in the treatment of arterial and venous embolism. Furthermore, pharmacodynamics and drug interactions regarding new anticoagulants will be reported.
引用
收藏
页码：921 / 935
页数：15
相关论文
共 110 条
  • [1] Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism A Systematic Review
    Adam, Soheir S.
    McDuffie, Jennifer R.
    Ortel, Thomas L.
    Williams, John W., Jr.
    [J]. ANNALS OF INTERNAL MEDICINE, 2012, 157 (11) : 796 - +
  • [2] Oral Anticoagulant Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
    Ageno, Walter
    Gallus, Alexander S.
    Wittkowsky, Ann
    Crowther, Mark
    Hylek, Elaine M.
    Palareti, Gualtiero
    [J]. CHEST, 2012, 141 (02) : E44S - E88S
  • [3] Ageno Walter, 2009, Expert Rev Cardiovasc Ther, V7, P569, DOI 10.1586/erc.09.37
  • [4] A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement
    Agnelli, G.
    Haas, S.
    Ginsberg, J. S.
    Krueger, K. A.
    Dmitrienko, A.
    Brandt, J. T.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (04) : 746 - 753
  • [5] Oral Apixaban for the Treatment of Acute Venous Thromboembolism
    Agnelli, Giancarlo
    Buller, Harry R.
    Cohen, Alexander
    Curto, Madelyn
    Gallus, Alexander S.
    Johnson, Margot
    Masiukiewicz, Urszula
    Pak, Raphael
    Thompson, John
    Raskob, Gary E.
    Weitz, Jeffrey I.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (09) : 799 - 808
  • [6] Apixaban for Extended Treatment of Venous Thromboembolism
    Agnelli, Giancarlo
    Buller, Harry R.
    Cohen, Alexander
    Curto, Madelyn
    Gallus, Alexander S.
    Johnson, Margot
    Porcari, Anthony
    Raskob, Gary E.
    Weitz, Jeffrey I.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (08) : 699 - 708
  • [7] Oral anticoagulation with edoxaban Focus on current phase III clinical development
    Ahrens, I.
    Bode, C.
    [J]. HAMOSTASEOLOGIE, 2012, 32 (03): : 212 - 215
  • [8] Ahrens I, 2012, FUTUR CARDIOL, V8, P533, DOI [10.2217/FCA.12.26, 10.2217/fca.12.26]
  • [9] Ahrens I, 2012, DISCOV MED, V13, P445
  • [10] Ahrens I, 2012, DISCOV MED, V13, P433
12345678910